Table 2 Summary of patient demographics, history and disease severity.
From: Suppressed renoprotective purines in COVID-19 patients with acute kidney injury
No AKI | AKI | P-value | |
|---|---|---|---|
Sample size | 23 | 21 | |
Age (years) | 58.0a [42.2, 64.6]b | 67.0a [62.0, 73.2]b | 0.02 |
Body mass index (kg/m2) | 31.8a [29.5, 39.3]b | 29.7a [27.1, 34.7]b | 0.2 |
Male (%) | 13 (56.5) | 14 (66.7) | 0.7 |
Race | |||
African American (%) | 6 (26.1) | 5 (23.8) | 0.32 |
Caucasian (%) | 17 (73.9) | 14 (66.7) | |
Not specified (%) | 0 (0.0) | 2 (9.5) | |
History of COPD (%) | 1 (4.3) | 3 (14.3) | 0.53 |
History of immunosuppression (%) | 2 (8.7) | 4 (19.0) | 0.58 |
History of CRF (%) | 1 (4.3) | 2 (9.5) | 0.93 |
History of alcohol (%) | 23 (100.0) | 21 (100.0) | 1.0 |
Active neoplasm (%) | 1 (4.3) | 1 (4.8) | 1.0 |
ICU patient (%) | 17 (73.9) | 15 (71.4) | 1.0 |
WHO Ordinal Scale of Severity | 6.0a [5.0, 7.5]b | 6.0a [5.0, 7.0]b | 0.83 |
Intubated (%) | 11 (47.8) | 7 (33.3) | 0.5 |
Veno-Venous ECMO (%) | 4 (33.3) | 0 (0.0) | 0.12 |
